The Effects of Cilnidipine on Metabolic Syndrome Improvement
A Multi-Center, Double-Blind, Randomized, Superiority Clinical Study to Compare the Effects of Cilnidipine on Metabolic Syndrome Improvement With Nifedipine GITS in Hypertensive Patients With Metabolic Syndrome (Phase IV) [SLIMS]
Sponsor: Boryung Pharmaceutical Co., Ltd
A PHASE4 clinical study on Hypertension and Metabolic Syndrome X, this trial is completed. The trial is conducted by Boryung Pharmaceutical Co., Ltd and has accumulated 7 data snapshots since 2005. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Study Description(click to expand)* Multi-center, randomized, prospective, double blind, active control, parallel study
* Superiority study (Treatment group - Cilnidipine/Control group - Nifedipine)
* Measure the effects of Cinalong(TM) after 3 month and 12 month-application
* Multi-center, randomized, prospective, double blind, active control, parallel study * Superiority study (Treatment group - Cilnidipine/Control group - Nifedipine) * Measure the effects of Cinalong(TM) after 3 month and 12 month-application
Status Flow
Change History
7 versions recorded-
Jan 2026 — Present [monthly]
Completed PHASE4
-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE4
First recorded
Jul 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Boryung Pharmaceutical Co., Ltd
For direct contact, visit the study record on ClinicalTrials.gov .